Statins and risk of cancer: a systematic review and metaanalysis (Q34585294)

3 August 2017

0 references

1 reference

title

Statins and risk of cancer: a systematic review and metaanalysis (English)

1 reference

3 August 2017

1 reference

1 reference

Richard M Martin

2

0 references

author name string

Danielle R L Browning

series ordinal

1

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 February 2007

1 reference

International Journal of Cancer

3 August 2017

published in

1 reference

3 August 2017

volume

120

1 reference

3 August 2017

issue

4

1 reference

3 August 2017

page(s)

833-843

1 reference

Carcinogenicity of lipid-lowering drugs

3 August 2017

cites work

1 reference

Statin use and the risk of breast and prostate cancer

21 January 2018

1 reference

Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project

21 January 2018

1 reference

Statins and the risk of colorectal cancer

21 January 2018

1 reference

Statins and prostate cancer risk: a case-control study

21 January 2018

1 reference

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

Statins and cancer risk: a meta-analysis

21 January 2018

1 reference

Should we lower cholesterol as much as possible?

21 January 2018

1 reference

Do statins cause cancer? A meta-analysis of large randomized clinical trials

21 January 2018

1 reference

Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies.

21 January 2018

1 reference

Mevalonate promotes the growth of tumors derived from human cancer cells in vivo and stimulates proliferation in vitro with enhanced cyclin-dependent kinase-2 activity

21 January 2018

1 reference

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

Statin use and cancer risk in the General Practice Research Database

21 January 2018

1 reference

The hazards of scoring the quality of clinical trials for meta-analysis

21 January 2018

1 reference

Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors

21 January 2018

1 reference

Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update

21 January 2018

1 reference

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

21 January 2018

1 reference

Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials

21 January 2018

1 reference

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin

21 January 2018

1 reference

Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women

21 January 2018

1 reference

Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up

21 January 2018

1 reference

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

21 January 2018

1 reference

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S).

21 January 2018

1 reference

Statin use, hyperlipidaemia, and the risk of breast cancer

21 January 2018

1 reference

The association between 3-hydroxy-3-methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study.

21 January 2018

1 reference

Serum lipids, lipid-lowering drugs, and the risk of breast cancer

21 January 2018

1 reference

Cancer risk among statin users: a population-based cohort study

21 January 2018

1 reference

Data dredging, bias, or confounding

21 January 2018

1 reference

Statins and cancer development.

21 January 2018

1 reference

Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.22366

1 reference

3 August 2017

1 reference